Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Endocrine
Published in: Endocrine 3/2018

01-06-2018 | Research Letter

Bone safety of dual-release hydrocortisone in patients with hypopituitarism

Authors: Stefano Frara, Sabrina Chiloiro, Teresa Porcelli, Antonella Giampietro, Gherardo Mazziotti, Laura De Marinis, Andrea Giustina

Published in: Endocrine | Issue 3/2018

Login to get access

Excerpt

Glucocorticoid-induced osteoporosis is the most common cause of secondary osteoporosis in both sexes [1, 2]. The glucocorticoid-induced decline in bone formation is associated with an increased fracture risk related both to the dose and duration of glucocorticoid treatment [3, 4]. …
Literature
1.
G. Mazziotti, A.M. Formenti, S. Frara, E. Roca, P. Mortini, A. Berruti, A. Giustina, Management of endocrine disease: risk of overtreatment of patients with adrenal insufficiency: current and emerging aspects. Eur. J. Endocrinol. 177, R231–R248 (2017)CrossRefPubMed
2.
E. Canalis, G. Mazziotti, A. Giustina, J.P. Bilezikian, Glucocorticoid-induced osteoporosis: pathophysiology and therapy. Osteoporos. Int. 18, 1319–1328 (2007)CrossRefPubMed
3.
G. Mazziotti, A.M. Formenti, R.A. Adler, J.P. Bilezikian, A. Grossman, E. Sbardella, S. Minisola, A. Giustina, Glucocorticoid-induced osteoporosis: pathophysiological role of GH/IGF-I and PTH/vitamin D axes, treatment options and guidelines. Endocrine 54, 603–611 (2016)CrossRefPubMed
4.
A. Angeli, G. Guglielmi, A. Dovio, G. Capelli, D. de Feo, S. Giannini, R. giorgino, L. Moro, A. Giustina, High prevalence of asymptomatic vertebral fractures in post-menopausal women receiving chronic glucocorticoid therapy: a cross-sectional outpatient study. Bone 39, 253–259 (2006)CrossRefPubMed
5.
G. Johannsson, A. Falorni, S. Skrtic, H. Lennernäs, M. Quinckler, J.P. Monson, P.M. Stewart, Adrenal insufficiency: review of clinical oucomes with current glucocorticoid replacement therapy. Clin. Endocrinol. 82, 2–11 (2015)CrossRef
6.
C. Hammarstrand, O. Ragnarsson, T. Hallén, T. Skoglund, A.G. Nilsson, G. Johannsson, D.S. Olsson, Higher glucocorticoid replacement doses are associated with increased mortality in patients with pituitary adenoma. Eur. J. Endocrinol. 177, 251–256 (2017)CrossRefPubMed
7.
V. Camozzi, C. Betterle, A.C. Frigo, V. Zaccariotto, M. Zaninotto, E. De Caneva, P. Lucato, W. Gomiero, S. Garelli, C. Sabbadin, M. Salvà, M. Dalla Costa, M. Boscaro, G. Luisetto, Vertebral fractures assessed with dual-energy X-ray absorptiometry in patients with Addison’s disease on glucocorticoid and mineralocorticoid replacement therapy. Endocrine https://​doi.​org/​10.​1007/​s12020-017-1380-8 (2017)
8.
A. Giustina, A.R. Bussi, C. Jacobello, W.B. Wehrenberg, Effects of recombinant human growth hormone (GH) on bone and intermediary metabolism in patients receiving chronic glucocorticoid treatment with suppressed endogenous GH response to GH-releasing horomne. J. Clin. Endocrinol. Metab. 80, 122–129 (1995)PubMed
9.
G. Mazziotti, T. Porcelli, A. Bianchi, V. Cimino, I. Patelli, C. Mejia, A. Fusco, A. Giampietro, L. De Marinis, A. Giustina, Glucocortioid replacement therapy and vertebral fractures in hypopituitary adult males with GH deficiency. Eur. J. Endocrinol. 163, 15–20 (2010)CrossRefPubMed
10.
G. Johannsson, R. Bergthorsdottir, A.G. Nilsson, H. Lennernas, T. Hedner, S. Skrtic, Improving glucocorticoid replacement therapy using a novel modified-release hydrocortisone tablet: a pharmacokinetic study. Eur. J. Endocrinol. 161, 119–130 (2009)CrossRefPubMed
11.
G. Johannsson, A.G. Nilsson, R. Bergthorsdottir, P. Burman, P. Dahlgvist, B. Ekman, B.E. Engström, T. Olsson, O. Ragnarsson, M. Ryberg, J. Wahlberg, B.M. Biller, J.P. Monson, P.M. Stewart, H. Lennernäs, S. Skrtic, Improved cortisol exposure-time profile and outcome in patients with adrenal insufficiency: a prospective randomized trial of a novel hydrocortisone dual-release formulation. J. Clin. Endocrinol. Metab. 97, 473–481 (2012)CrossRefPubMed
12.
R. Giordano, F. Guaraldi, E. Marinazzo, F. Fumarola, A. Rampino, R. Berardelli, I. Karamouzis, M. Lucchiari, T. Manetta, G. Mengozzi, E. Arvat, E. Ghigo, Improvement of anthropometric and metabolic parameters, and quality of life following treatment with dual-release hydrocortisone in patients with Addison’s disease. Endocrine 51, 360–368 (2016)CrossRefPubMed
13.
14.
J.T. Schousboe, J.A. Shepherd, J.P. Bilezikian, S. Baim, Executive summary of the 2013 international society for clinical densitometry position development conference on bone densitometry. J. Clin. Densitom. 16, 455–466 (2013)CrossRefPubMed
15.
D.E. Henley, S.L. Lightman, Cardio-metabolic consequences of glucocorticoid replacement: relevance of ultradian signalling. Clin. Endocrinol. 80, 621–628 (2014)CrossRef
16.
S.W. Ing, L.T. Sinnott, S. Donepudi, E.A. Dabies, R.P. Pelletier, N.E. Lane, Change in bone mineral density at one year following glucocorticoid with drawal in kidney transplant recipients. Clin. Transplant. 25, E113–E123 (2011)CrossRefPubMed
17.
G. Martí, R. Gómez, E. Jódar, C. Loinaz, E. Moreno, E. Hawkins, Long-term follow-up of bone mass after orthotopic liver transplantation: effect of steroid withdrawal from the immunosuppressive regimen. Osteoporos. Int. 13, 147–150 (2002)CrossRef
18.
G. Mazziotti, A. Bianchi, S. Bonadonna, M. Nuzzo, V. Cimino, A. Fusco, L. De Marinis, A. Giustina, Increased prevalence of radiological spinal deformities in adult patients with GH deficiency: influence of GH replacement therapy. J. Bone Miner. Res. 21, 520–528 (2006)CrossRefPubMed
19.
G. Mazziotti, A. Giustina, Glucocorticoids and the regulation of growth hormone secretion. Nat. Rev. Endocrinol. 9, 265–276 (2013)CrossRefPubMed
20.
21.
A. Giustina, G. Mazziotti, Growth hormone replacement therapy and fracture risk. Lancet Diabetes Endocrinol. 3, 307–308 (2015)CrossRefPubMed
22.
M. Quinkler, R.M. Nilsen, K. Zopf, M. Ventz, M. Øksnes, Modified-release hydrocortisone decreases BMI and HbA1c in patients with primary and secondary adrenal insufficiency. Eur. J. Endocrinol. 172, 619–626 (2015)CrossRefPubMed
Metadata
Title
Bone safety of dual-release hydrocortisone in patients with hypopituitarism
Authors
Stefano Frara
Sabrina Chiloiro
Teresa Porcelli
Antonella Giampietro
Gherardo Mazziotti
Laura De Marinis
Andrea Giustina
Publication date
01-06-2018
Publisher
Springer US
Published in
Endocrine / Issue 3/2018
Print ISSN: 1355-008X
Electronic ISSN: 1559-0100
DOI
https://doi.org/10.1007/s12020-017-1512-1

Other articles of this Issue 3/2018

Endocrine 3/2018 Go to the issue

Endocrine Surgery

Duodeno-jejunal bypass restores β-cell hypersecretion and islet hypertrophy in western diet obese rats

Research Letter

Brown tumors of primary hyperparathyroidism may be a source of extrarenal 1,25-dihydroxyvitamin D production

Original Article

Sexual function and sex hormones in breast cancer patients

Letter to the Editor

Impact of noninvasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP) on the risk of malignancy estimated by the ultrasonographic classification of the American Thyroid Association (ATA) in thyroid nodules >1 cm

Original Article

Association between LEPR, FTO, MC4R, and PPARG-2 polymorphisms with obesity traits and metabolic phenotypes in school-aged children

Endocrine Surgery

Predictors of surgical outcome and early criteria of remission in acromegaly
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits